Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. (2014)

First Author: Voit T
Attributed to:  MICA: MRC Centre for Neuromuscular Diseases funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S1474-4422(14)70195-4

PubMed Identifier: 25209738

Publication URI: http://europepmc.org/abstract/MED/25209738

Type: Journal Article/Review

Volume: 13

Parent Publication: The Lancet. Neurology

Issue: 10

ISSN: 1474-4422